Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2025 | Updates in the PROBASE study of risk adapted screening for prostate cancer

Peter Albers • 18 Mar 2025
EAU 2025
Genitourinary Cancer Prostate Cancer
PROBASE

Peter Albers, German Cancer Research Center (DKFZ), Heidelberg & Heinrich-Heine-University, Düsseldorf, Germany, comments on the PROBASE trial of risk adapted screening for prostate cancer and its findings. Men who have been biopsied with a negative finding are unlikely to develop prostate cancer in the next five years and duplicating PSA values are important to reduce the high-risk group that needs diagnosis. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Peter Albers

The case for increased screening in prostate cancer
2:57
The case for increased screening in prostate cancer
Peter Albers • 18 Mar 2025
Developing novel early detection techniques in prostate cancer
2:20
Developing novel early detection techniques in prostate cancer
Peter Albers • 18 Mar 2025
Novel MRI approach for prostate cancer screening
3:14
Novel MRI approach for prostate cancer screening
Peter Albers • 8 Jul 2021
Surgery in metastatic germ cell tumors to reduce disease burden and improve long-term outcomes
3:40
Surgery in metastatic germ cell tumors to reduce disease burden and improve long-term outcomes
Peter Albers • 8 Jul 2021

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals